(Q33782796)

29 July 2017

Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program (English)

1 reference

29 July 2017

0 references

anti-retroviral agent

0 references

10

Max Essex

1 reference

29 July 2017

3

Ndwapi Ndwapi

1 reference

29 July 2017

5

Tendani Gaolathe

1 reference

29 July 2017

9

Khumo Seipone

1 reference

29 July 2017

Hermann Bussmann

1

1 reference

29 July 2017

C William Wester

2

1 reference

29 July 2017

Nicolas Grundmann

4

1 reference

29 July 2017

John Puvimanasinghe

6

1 reference

29 July 2017

Ava Avalos

7

1 reference

29 July 2017

Madisa Mine

8

1 reference

29 July 2017

Victor Degruttola

11

1 reference

29 July 2017

Richard G Marlink

12

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 November 2008

1 reference

29 July 2017

1 reference

29 July 2017

22

1 reference

29 July 2017

17

1 reference

29 July 2017

2303-2311

1 reference

Two-year virologic outcomes of an alternative AIDS care model: evaluation of a peer health worker and nurse-staffed community-based program in Uganda

29 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853026

Strengthening healthcare capacity through a responsive, country-specific, training standard: the KITSO AIDS training program's support of Botswana's national antiretroviral therapy rollout

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853026

Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853026

Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853026

High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853026

Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853026

Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853026

Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853026

Establishment of a public antiretroviral treatment clinic for adults in urban Botswana: lessons learned

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853026

Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853026

World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853026

CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853026

Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853026

Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853026

Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853026

Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853026

Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853026

Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853026

The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853026

Determinants of Mortality and Nondeath Losses from an Antiretroviral Treatment Service in South Africa: Implications for Program Evaluation

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2853026

Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort

30 October 2018

1 reference

12 December 2020

Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa

1 reference

12 December 2020

Incidence of tuberculosis during highly active antiretroviral therapy in high-income and low-income countries

1 reference

12 December 2020

Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design

1 reference

12 December 2020

10.1097/QAD.0B013E3283129DB0

Identifiers

DOI

1 reference

29 July 2017

1 reference

29 July 2017

1 reference